153 related articles for article (PubMed ID: 36143386)
41. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
[TBL] [Abstract][Full Text] [Related]
42. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
[TBL] [Abstract][Full Text] [Related]
43. Dynamic contrast-enhanced MRI versus
Feng F; Qiang F; Shen A; Shi D; Fu A; Li H; Zhang M; Xia G; Cao P
Chin J Cancer Res; 2018 Feb; 30(1):21-30. PubMed ID: 29545716
[TBL] [Abstract][Full Text] [Related]
44. Differential diagnostic value of
Li X; Wu N; Zhang W; Liu Y; Ming Y
J Bone Oncol; 2020 Oct; 24():100302. PubMed ID: 32760643
[TBL] [Abstract][Full Text] [Related]
45. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
46. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
47. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
Ponisio MR; McConathy J; Laforest R; Khanna G
Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
[TBL] [Abstract][Full Text] [Related]
50. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
51. Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?
van Hoeij FB; Keijsers RG; Loffeld BC; Dun G; Stadhouders PH; Weusten BL
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):66-71. PubMed ID: 25139518
[TBL] [Abstract][Full Text] [Related]
52. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
53. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
54. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
55. Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.
Nishii R; Saga T; Sudo H; Togawa T; Kuyama J; Tani T; Maeda T; Kobayashi M; Iizasa T; Shingyoji M; Itami M; Kawamura K; Hashimoto H; Yamazaki K; Tamura K; Higashi T
Ann Nucl Med; 2021 Feb; 35(2):211-222. PubMed ID: 33387282
[TBL] [Abstract][Full Text] [Related]
56. Role of 18F-FDG PET/CT in patients affected by pulmonary primary lymphoma.
Peng Y; Qi W; Luo Z; Zeng Q; Huang Y; Wang Y; Sharma A; Schmidt-Wolf IGH; Liao F
Front Oncol; 2022; 12():973109. PubMed ID: 36185301
[TBL] [Abstract][Full Text] [Related]
57. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
58. Characteristics of malignant thyroid lesions on [
Nasr H; Farghaly H; Alqarni A; Al-Salem S; Sayed M
Eur J Radiol Open; 2021; 8():100373. PubMed ID: 34458507
[TBL] [Abstract][Full Text] [Related]
59. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of physiologic and abnormal glucose uptake in palatine tonsils: differential diagnostics with sequential dual-time-point 2-deoxy-2-[18F]FDG PET/CT.
Pietrzak AK; Kazmierska J; Marszalek A; Cholewinski W
Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):299-306. PubMed ID: 30221906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
